Trial Profile
A trial of natalizumab and fingolimod for the treatment of patients with multiple sclerosis and detection of genetic variations to plasma cytokine receptor levels during treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Feb 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 26 Feb 2016 New trial record